Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Continuous low-dose cytokine infusion therapy|
|Abstract:||A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.|
|Inventor(s):||Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ)|
|Assignee:||Schering Corporation (Kenilworth, NJ)|
1. A method of treating a hepatitis C viral infection in a human comprising continuously parenterally administering interferon alpha to the human in an amount from about 2
million IU per week to about 10 million IU per week.
2. The method of claim 1 wherein said continuous administration is conducted subcutaneously.
3. The method of claim 1 wherein said continuous administration is conducted by injection of a sustained-release formulation of the interferon alpha.
4. The method of claim 1 wherein said continuous administration is accomplished by injection of a polymer-interferon alpha conjugate.
5. The method of claim 4 wherein the polymer is polyethylene glycol.
6. The method of claim 1 wherein the interferon alpha is interferon alpha-2b.
7. The method of any one of claims 1, 2, 3, 4, 5 or 6 wherein the interferon alpha is used in combination with ribavirin.
8. The method of claim 1 wherein the interferon alpha is used in combination with at least one other cytokine selected from the group consisting of G-CSF, GM-CSF, IL-1, IL-3, IL-6 and erythropoietin.
9. The method of claim 1 wherein said amount is about 2 million IU interferon alpha per week.
10. The method of claim 1 wherein said amount is from about 2 to 5 million IU interferon alpha per week.
11. The method of claim 1 wherein said amount is from about 2 to 8 million IU interferon alpha per week.
12. The method of claim 1 wherein said amount is from 5 to 8 million IU interferon alpha per week.
13. The method of claim 1 wherein said amount is 5 million IU interferon alpha per week.
14. The method of claim 1 wherein said amount is 8 million IU interferon alpha per week.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.